-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Infants (<1 year)
-
Children (1-11 years)
-
Adolescents (12-17 years)
-
Hospital
-
SARS-CoV-2
-
Respiratory syncytial virus
-
Influenza virus
-
Adenovirus
-
Rhinovirus
-
Human metapneumovirus
-
Parainfluenza Virus
-
Enterovirus
-
Bordetella pertussis
-
Seasonal coronavirus
-
Bordetella parapertussis
-
Chlamydia pneumoniae
-
Mycoplasma pneumoniae
-
Influenza-like illness/Acute respiratory infection
-
Diagnostics
-
Point of care tests
-
General population
-
Infants (<1 year)
-
Children (1-11 years)
-
Hospital
-
Respiratory syncytial virus
-
General population
-
Infants (<1 year)
-
Children (1-11 years)
-
Primary care
-
Respiratory syncytial virus
-
General population
-
Infants (<1 year)
-
Children (1-11 years)
-
Hospital
-
Emergency department
-
Respiratory syncytial virus
-
General population
-
Infants (<1 year)
-
Children (1-11 years)
-
Hospital
-
Emergency department
-
Respiratory syncytial virus
-
General population
-
Infants (<1 year)
-
Children (1-11 years)
-
Hospital
-
Respiratory syncytial virus
-
Blood sample
-
Nasopharyngeal swab
-
Nasal lining fluid sample
-
General population
-
Infants (<1 year)
-
Children (1-11 years)
-
Hospital
-
Emergency department
-
Respiratory syncytial virus
-
General population
-
Infants (<1 year)
-
Children (1-11 years)
-
Adolescents (12-17 years)
-
Hospital
-
Intensive care unit
-
Respiratory syncytial virus
-
General population
-
Infants (<1 year)
-
Children (1-11 years)
-
Hospital
-
Primary care
-
Respiratory syncytial virus
-
Pharmacological intervention
-
Monoclonal antibodies
-
Nirsevimab
-
General population
-
Infants (<1 year)
-
Children (1-11 years)
-
Primary care
-
Respiratory syncytial virus
-
Pharmacological intervention
-
Monoclonal antibodies
-
Nirsevimab